Antiretroviral treatment is crucial in reducing the risk of HIV transmission and preventing the progression to AIDS. This study assessed the efficacy of the AZT+3TC+NVP therapeutic regimen in treating HIV. The retrospective study included 445 HIV-1 seropositive patients monitored from 2014 to 2021. Notably, 73.5% achieved undetectable viral loads at 12 months, with variations in suppression based on gender and age. At 18 months, 80.2% maintained suppressed viral loads, while therapeutic failure remained relatively low. The AZT+3TC+NVP regimen emerged as a cost-effective and efficient option for resource-limited regions.